ReDVA is a joint industry-academic research programme. It involves a number of partners: University of Dundee, Queen Elizabeth Hospital, Birmingham, Guerbet, Villipinte France, University of Limerick, Ireland & Vascular Flow Technologies, Dundee.
University of Dundee
The University of Dundee is one of the UK’s leading universities, internationally recognised for its expertise across a range of disciplines including science, medicine and engineering.
University of Limerick
The University of Limerick is a distinctive, pioneering and connected university that shapes the future through educating and empowering people to meet the real challenges of tomorrow. At a time of profound and rapid societal change and a significant evolution in the role of universities UL has delivered innovative teaching, created better learning experiences for our students, undertaken world-class research and made ever-stronger contributions to meeting Ireland’s needs.
University Hospital Birmingham NHS Foundation Trust
University Hospitals Birmingham NHS Foundation Trust (UHB) is the leading university teaching hospital in the West Midlands and is one of the most consistently high performing trusts in the NHS.
The Trust provides a full range of services, has a large renal (kidney) programme and is a specialist centre for burns and plastic surgery, organ transplants, neuroscience and cancer.
During 2012/13, the Trust treated more patients than ever before. It completed more that 585,000 outpatient appointments, 125,000 inpatient treatments and more than 94,000 A&E attendances.
Vascular Flow Technologies Limited
Vascular Flow Technologies is a dynamic global medical devices company focused on the research, development and commercialisation of vascular devices based on a new understanding of blood flow dynamics – Spiral Laminar Flo™ (SLF™ technology).
Our innovative technology is currently applied to two synthetic grafts, Our SLF™ PV graft and our SLF™ AV graft. Vascular Flow grafts are the ONLY grafts proven to induce Spiral Laminar Flow™, the body’s natural blood flow pattern, improving graft patency and helping to prevent disease progression resulting in better outcomes for the surgeon, care-giver and patient.
Guerbet’s Research and Development operations serve a dual purpose:
- design, develop and market imaging solutions that meet the needs of health professionals;
- contribute to improved patient management in three major fields: oncology, cardiovascular diseases and neuro-degenerative disorders.
With an annual budget corresponding to 10% of the company’s turnover and a dedicated headcount of 180, Guerbet’s R&D is a vector for independence and technological innovation.
Associate Partner – University of Edinburgh